Mankind Pharma Ltd (MANKIND) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.17x

Mankind Pharma Ltd (MANKIND) has a Cash Flow Reinvestment Rate of 0.17x as of September 2025, reinvesting Rs2.71 Billion (capex Rs2.71 Billion ) from operating cash flow of Rs16.37 Billion. See MANKIND FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.17x
(Capex + Investments) / Operating CF

Total Reinvested

Rs2.71 Billion
Capex + Investments

Operating Cash Flow

Rs16.37 Billion
INR

Capital Expenditures

Rs2.71 Billion
INR

Mankind Pharma Ltd Cash Flow Reinvestment Rate (2019–2026)

Historical reinvestment intensity for Mankind Pharma Ltd across 8 annual periods. For the full cash flow conversion analysis, see Mankind Pharma Ltd cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Mankind Pharma Ltd (2019–2026)

Year-by-year capital reinvestment analysis for Mankind Pharma Ltd. See Mankind Pharma Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (INR) Operating CF Capex YoY Change
2026 0.44x Rs10.98 Billion Rs25.16 Billion Rs6.26 Billion ▼ -22.3%
2025 0.56x Rs13.56 Billion Rs24.13 Billion Rs4.61 Billion ▼ -43.2%
2024 0.99x Rs21.29 Billion Rs21.52 Billion Rs3.82 Billion ▲ +76.2%
2023 0.56x Rs10.17 Billion Rs18.13 Billion Rs8.32 Billion ▼ -86.1%
2022 4.04x Rs37.15 Billion Rs9.20 Billion Rs23.46 Billion ▲ +199.3%
2021 1.35x Rs15.35 Billion Rs11.37 Billion Rs3.12 Billion ▲ +116.4%
2020 0.62x Rs6.67 Billion Rs10.70 Billion Rs2.28 Billion ▲ +25.8%
2019 0.50x Rs2.98 Billion Rs6.00 Billion Rs2.98 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow